866-997-4948(US-Canada Toll Free)

Oblean (Obesity) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Oct 2013

Category :

Metabolic Disorders

No. of Pages : 46 Pages


After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade. The main drivers of growth will be a large overweight and obese population that need pharmacological intervention, the increasingly frequent prescription of pharmacological therapy as physicians make preemptive efforts to curtail disease progression with earlier treatment, as well as greater responsibility of third party payers for reimbursement and thus allow greater access of medications to patients.

Norgine and Takedas Oblean (cetilistat) received Japanese regulatory approval for the treatment of obesity with complications in September 2013, less than one year after the NDA was submitted to the Ministry of Health, Labour and Welfare (MHLW). This compound was originally developed by UK-based Alizyme Therapeutics Limited and was acquired by Norgine in October 2009. Oblean has comparable efficacy to Xenical in inducing weight loss, but with a more favorable gastrointestinal side effect profile

Scope

  • Overview of obesity, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Oblean including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Oblean for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, China, Brazil, Japan and Canada

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for obesity.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Oblean performance
  • Obtain sales forecast for Oblean from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, China, Brazil, Japan and Canada)
Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10

3 Disease Overview 11
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 14
3.1.4 Quality of Life 15
3.2 Symptoms 15

4 Disease Management 16
4.1 Treatment Overview 16

5 Competitive Assessment 22
5.1 Overview 22
5.2 Strategic Competitor Assessment 26

6 Oblean (cetilistat) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Safety 30
6.4 SWOT Analysis 30
6.5 Forecast 31

7 Appendix 32
7.1 Bibliography 32
7.2 Abbreviations 35
7.3 Research Methodology 36
7.4 Forecasting Methodology 36
7.4.1 Percent Drug-Treated Obesity Patients 37
7.4.2 Key Launch Dates 37
7.4.3 General Pricing Assumptions 37
7.4.4 Individual Drug Assumptions 38
7.4.5 Generic Erosion 38
7.5 Physicians, Specialists, and Payers Included in This Study 39
7.6 About the Authors 42
7.6.1 Analysts 42
7.6.2 Therapy Director - CVMD and Infectious Disease 43
7.6.3 Director - Medical Devices 43
7.6.4 Global Head of Healthcare 44
7.7 About GlobalData 45
7.8 Disclaimer 45

List of Table


Table 1: Target Pathways in the Treatment of Obesity 14
Table 2: Symptoms of Obesity 15
Table 3: Treatment Guidelines for Obesity 19
Table 4: Most Prescribed Drugs for Obesity by Class in the Global Markets, 2013 20
Table 5: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk 21
Table 6: Bariatric Treatment Attributes 25
Table 7: Leading Drug Treatments for Obesity, 2013 26
Table 8: Marketed Obesity Treatment Devices by Type 27
Table 9: Product Profile - Oblean 29
Table 10: ObleanSWOT Analysis, 2013 30
Table 11: Global Sales Forecasts ($m) for Oblean, 2012-2022 31
Table 12: Key Launch Dates - Oblean 37

List of Chart


Figure 1: Treatment Algorithm for Obesity 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *